For the clinical treatment of gold nanometers, in addition to this scientific research group, there are two other scientific research groups.

After Huang Xiuyuan encouraged a group of researchers, Zhao Xiaojun and Mo Siqian took him to the work area of ​​another scientific research group next door.

The research group's research topic is the special inhibitory effect of gold nanocrystal particles.

After taking an experimental report, he looked through it for a while, and Mo Siqian, who was beside him, explained some of the key points from time to time.

"The results of this group's research are about the combination of gold nano-45 crystals and antagonists, and have completed two small directions of conquest..."

Huang Xiuyuan looked at it and found that the special inhibitory effect of gold nanocrystals comes from its own multivalent effect.

The multivalent effect can achieve extremely high selectivity and sensitivity within the organism, reducing interference and weakening in complex biochemical environments in the body.

At present, this scientific research team has successfully improved the TAK-779 antagonist, which has increased its inhibitory effect on HIV by about 18 to 28 times, and most of the side effects have been eliminated.

TAK-779 is an old product from the 1990s. The current patent period has passed and this drug has long been eliminated.

The reason for being eliminated is mainly because the first generation of TAK-779 contains an ammonium salt, which is a highly toxic compound. The effective molecules in TAK-779 must be combined with ammonium salt to ensure an inhibitory effect.

Ammonium salts with extremely strong toxicity cause serious harm to the human body, just like the current chemotherapy, which makes patients worse than death.

The research team's approach is to use gold nanocrystals to replace ammonium salts and combine with effective molecules in TAK-779, which improves the inhibitory effect and eliminates the toxicity of ammonium salts.

"Yes, although there are limitations, the progress is huge." Huang Xiuyuan handed the tablet to the researcher beside him.

Mo Siqian, who is in charge of the research project, knows the shortcomings of Jinnan-TAK-779: "At present, it can only be effective for some AIDS patients, and further research is needed."

The disadvantage of gold nano-TAK-779 is mainly due to the research and development ideas of the drug itself. This drug can only resist HIV containing the CCR5 receptor, while HIV with the CXCR4 and CCR5-CXCR4 receptors is not effective.

However, this drug can be used in addition to treating AIDS, but also in the inhibition of metastasis of tumor cells, because tumor cells also have CCR5 receptors.

"By the way, Lao Mo, what's the situation with the AIDS vaccine?"

Mo Siqian replied helplessly: "One word is difficult. The mutation of HIV is too fast. It will be mutated beyond recognition in the human body, even in a few months. Many vaccines can only be protected for a few months. This is definitely a loss-making deal for R&D companies."

The difficulty of developing viral vaccines, especially RNA viruses with high mutagenic rates, is basically a solution-free situation at present.

The speed of human vaccine development cannot keep up with the speed of virus mutation. It is often a vaccine that has been developed for several years, but was killed by the virus after just a few months of use.

Faced with this desperate situation, which medical company dares to invest heavily? Even though they know they will lose all their money, they will definitely not bet on virus vaccines. At most, they will invest a little money in some trial research.

Even Shennong Group has not devoted much energy to AIDS vaccines, because the success rate of the vaccine is too low and there is no reasonable idea to fight against viruses with high mutation rates.

It is better to use the cocktail therapy now, that is, a combination of multiple inhibitors, which makes it difficult for HIV to fight against four hands and is not easy to develop drug resistance in a short period of time.

But there are some problems with cocktail therapy, that is, the side effects of the drug are inevitable and need to be taken for a long time, which causes great damage to the body.

Huang Xiuyuan thought for a moment, but remembered the future memory that the cell trap method that had been popular for a period of time before the nanobody robot.

"Lao Mo, I have an idea."

Hearing this, Mo Siqian picked up the tablet beside him and activated the recording function: "Chairman, please say, I'll listen carefully."

"Now, treating viral diseases depends on vaccines, humans' own immunity, or chemotherapy. When treating highly varied RNA viruses, they are often very passive."

Huang Xiuyuan continued: "We need to change our thinking. It is difficult for viruses to survive and replicate independently in the natural environment for a long time. We must rely on the DNA chain of cells to achieve reverse transcription and replication and achieve the purpose of reproduction."

"What does the chairman mean?" Mo Siqian asked curiously.

"My idea is to create a trap, induce the virus into this trap, and then kill it in a concentrated manner."

trap?

Induction?

The researchers were thinking.

Huang Xiuyuan opened a working computer and described some key points of the cell trap method through pictures and texts.

First, the patient's stem cells are extracted and cultured in vitro. The cultured stem cells are induced by radiation irradiation and transformed into cancer cells. Finally, gold nanorod particles are injected into these cancer cells, and then these stem cells are injected back into the patient's body.

The patient has taken a combination of cocktail therapy, which has temporarily suppressed HIV in the corner.

After the cancer cells enter the body, due to the medication of cocktail therapy, the cancer cells cannot be protected. HIV will enter the cancer cells and prepare to use the DNA chains of the cancer cells to perform reverse transcription and replication.

As long as you calculate the time, start near-infrared light exposure, burn these cancer cells, and kill them together with the HIV that enters the cancer cells.

However, this time must be calculated well, because the time for division and proliferation of cancer cells usually divides once every 4 weeks.

HIV usually replicates once every 52 hours, and HIV also likes to hide inside T cells and lurk in order to avoid drug hunting.

Based on this characteristic, when Huang Xiuyuan's stem cells are cultivated in vitro, they need to be directed to be born into T cells, and then turn T cells into cancer cells, allowing HIV to enter the inside of these cancer cells.

This cell trap method must also be combined with another drug, a drug that can release interferon-induce HIV from normal T cells and attract cancer cells.

In fact, the future cell trap method does not require gold nanorods, because future trap cancer cells are special cells after gene editing. Usually, a self-decomposition substance will be produced in about two days, killing the internal HIV and itself.

However, now, gene editing technology is not mature, and the use of gold nanorods as targets is also effective.

Mo Siqian quickly figured out the key: "Chairman, if the cell trap method is to be successful, the induction of interferon must 100% introduce the hidden virus of T cells, otherwise the virus will easily rekindle."

This problem is the key to HIV treatment and is also a problem facing many anti-diabetic drugs at present.

Huang Xiuyuan expressed his thoughts: "My thought is to interfere with the interior of normal T cells, creating an illusion that T cells are about to die, and these hidden HIV is forced to be activated for reverse transcription and replication."
Chapter completed!